These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23174382)

  • 21. Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load.
    Kourkounti S; Retsas T; Paparizos V; Tsimpidakis A; Kapsimali V; Rigopoulos D
    Vaccine; 2018 Mar; 36(12):1533-1536. PubMed ID: 29449101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy.
    Lao-Araya M; Puthanakit T; Aurpibul L; Taecharoenkul S; Sirisanthana T; Sirisanthana V
    Vaccine; 2011 May; 29(23):3977-81. PubMed ID: 21473954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients.
    Pettit NN; DePestel DD; Malani PN; Riddell J
    HIV Clin Trials; 2010; 11(6):332-9. PubMed ID: 21239361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of humoral response to recommended vaccines in HIV-infected adults.
    Tsachouridou O; Christaki E; Skoura L; Georgiou A; Nanoudis S; Vasdeki D; Ntziovara MA; Kotoreni G; Forozidou E; Tsoukra P; Germanidis G; Metallidis S
    Comp Immunol Microbiol Infect Dis; 2017 Oct; 54():27-33. PubMed ID: 28915998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection?
    Powis JE; Raboud J; Ostrowski M; Loutfy MR; Kovacs C; Walmsley SL
    J Infect Dis; 2012 May; 205(10):1534-8. PubMed ID: 22448009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
    Avdicova M; Crasta PD; Hardt K; Kovac M
    Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A two-dose hepatitis B vaccine for adults (Heplisav-B).
    Med Lett Drugs Ther; 2018 Jan; 60(1539):17-18. PubMed ID: 29364196
    [No Abstract]   [Full Text] [Related]  

  • 28. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients.
    Ungulkraiwit P; Jongjirawisan Y; Atamasirikul K; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2007 Jul; 38(4):680-5. PubMed ID: 17883006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 20 μg hepatitis B vaccination reduced the risk of low responsiveness in infants with HLA-II risk genotype of HBsAg positive mothers.
    Cao M; Wu Y; Wen S; Pan Y; Wang C; Zhang X; Kong F; Lu Y; Wang C; Niu J; Li J; Jiang J
    Infect Genet Evol; 2018 Sep; 63():243-248. PubMed ID: 29883771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load.
    Rey D; Krantz V; Partisani M; Schmitt MP; Meyer P; Libbrecht E; Wendling MJ; Vetter D; Nicolle M; Kempf-Durepaire G; Lang JM
    Vaccine; 2000 Jan; 18(13):1161-5. PubMed ID: 10649616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice.
    Mena G; Llupià A; García-Basteiro AL; Díez C; León A; García F; Bayas JM
    Vaccine; 2012 May; 30(24):3703-9. PubMed ID: 22446635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania.
    Pippi F; Bracciale L; Stolzuoli L; Giaccherini R; Montomoli E; Gentile C; Filetti S; De Luca A; Cellesi C
    HIV Med; 2008 Aug; 9(7):519-25. PubMed ID: 18554311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients.
    de Vries-Sluijs TE; Hansen BE; van Doornum GJ; Kauffmann RH; Leyten EM; Mudrikova T; Brinkman K; den Hollander JG; Kroon FP; Janssen HL; van der Ende ME; de Man RA
    J Infect Dis; 2011 Apr; 203(7):984-91. PubMed ID: 21266513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens.
    Flynn PM; Cunningham CK; Rudy B; Wilson CM; Kapogiannis B; Worrell C; Bethel J; Monte D; Bojan K;
    J Acquir Immune Defic Syndr; 2011 Apr; 56(4):325-32. PubMed ID: 21350366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Oral Levamisole Co-administration on the Level of Immune Response to Hepatitis B Vaccine in Healthy Individuals: A Randomized Clinical Trial.
    Hosseini M; Shalchiantabrizi P; Dadgarmoghaddam M; Ahmady-Simab S; Behjati A; Salari M
    Iran J Allergy Asthma Immunol; 2017 Jun; 16(3):219-227. PubMed ID: 28732435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
    Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
    Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART.
    Bekele Y; Yibeltal D; Bobosha K; Andargie TE; Lemma M; Gebre M; Mekonnen E; Habtewold A; Nilsson A; Aseffa A; Howe R; Chiodi F
    Sci Rep; 2017 Aug; 7(1):8956. PubMed ID: 28827754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV.
    Tedaldi EM; Baker RK; Moorman AC; Wood KC; Fuhrer J; McCabe RE; Holmberg SD;
    Clin Infect Dis; 2004 May; 38(10):1478-84. PubMed ID: 15156488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunisation after hepatitis B polyvalent vaccination among children in South Kivu Province, Democratic Republic of the Congo.
    Shindano TA; Mbusa RK; Kabamba BM; Fiasse R; Horsmans Y
    S Afr Med J; 2019 Apr; 109(5):319-322. PubMed ID: 31131798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response.
    Herrero-Fernández I; Pacheco YM; Genebat M; Rodriguez-Méndez MDM; Lozano MDC; Polaino MJ; Rosado-Sánchez I; Tarancón-Diez L; Muñoz-Fernández MÁ; Ruiz-Mateos E; Leal M
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.